Gastric outlet obstruction (GOO) is usually a late presentation of gastric cancer, pancreaticobiliary malignancy, and extrinsic lymph nodal compression. Presenting symptoms are abdominal pain, postprandial epigastric fullness, and recurrent vomiting, which lead to severe malnutrition and dehydration and poor quality of life (QoL). Endoscopic enteral stent placement has become the acceptable alternative modality for palliation of malignant GOO because it is safe, minimally invasive, and a cost-effective procedure. In addition, endoscopic stent placement leads to shorter time to resume oral diet and shorter hospital stay in comparison to surgical bypass. Endoscopic stent placement is associated with high technical as well as clinical success rates and improvement in QoL, but no survival improvement. Recurrence of symptoms occurs due to stent occlusion, or stent migration, which can be successfully managed with repeat endoscopic stent placement. Perforation and bleeding are serious but rare complications.
Introduction
G astric outlet obstruction (GOO) is usually a late presentation of gastric cancer, pancreaticobiliary malignancy, and extrinsic lymph nodal compression. [1, 2] Presenting symptoms are abdominal pain, postprandial epigastric fullness, and recurrent vomiting, which lead to severe malnutrition, dehydration and poor quality of life (QoL). [1, 3] All these factors result in diminished life expectancy. Once GOO is developed, mean life expectancy ranges from 7 to 20 weeks. [4, 5] Treatment of malignant GOO is mainly palliative. Surgical bypass is considered as a traditional measure of palliation of gastric outlet obstruction in these groups of patients. [6, 7] However, in these patients, surgical risk is high with perioperative complication rate of 25%-35% and mortality of up to 2%. [7, 8] Endoscopic enteral stent placement is an acceptable alternative of surgical management. Endoscopic treatment is shown to be associated with lower morbidity and mortality, shorter hospitalization, and earlier symptoms relief. [9] This article reviews the etiology of gastric outlet obstruction, outcomes, predictors of treatment failure, and QoL after endoscopic enteral stent placement. malignant GOO. [16] [17] [18] Bowel metastases from colon and pelvic malignancies and lymphadenopathy at porta hepatis are less common causes of malignant GOO. [19] 
Diagnosis of Gastric Outlet Obstruction
Diagnosis of GOO is based on history, physical examination, imaging, and endoscopy. Symptoms of GOO usually overlap with symptoms of underlying malignancy or adverse effects of different treatments such as chemotherapy and radiotherapy. This may cause a delay in diagnosis of GOO in these settings. Symptoms of GOO include nausea, vomiting, abdominal fullness, reflux, dehydration, anemia, and hypoalbuminemia. Blood gas analysis may show hypochloremic alkalosis. Succussion splash may be heard more than 3 h after meal in about half of the patients. [20] Barium-contrast studies are helpful not only for confirmation of GOO but also for its localization and to assess the length of stricture. Another cross-sectional imaging such as computerized tomography is extremely helpful for the diagnosis of underlying malignancy itself and site and length of gastroduodenal obstruction. Upper GI endoscopy is the gold standard with additional advantage of direct visualization and tissue sampling.
Methods of Palliation Gastric Outlet Obstruction
Conventionally, malignant GOO is treated with open gastrojejunostomy (OGJ). Although this procedure provides effective palliation of GOO symptoms, it results in considerable morbidity and mortality because of fragility of this group of patients. [21, 22] A systematic review of 12 studies demonstrated that endoscopic stent placement is preferable to OGJ in terms of shorter hospital stay and shorter time to oral intake. There was no significant difference in the rate of major complications and length of survival in the two groups. [23] Laparoscopic gastrojejunostomy (LGJ) is now preferred alternative of surgical management of malignant GOO. Three retrospective studies compared the results of LGJ and endoscopic stent placement. [6, 24, 25] Overall results showed shorter hospital stay, lesser postoperative pain and complications but reduced survival (56 vs. 119 days) following endoscopic stent placement. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a novel approach for palliation of malignant GOO. The first EUS-GE was described by Khashab et al. [26] A multicenter retrospective study showed that EUS-GE had comparable effectiveness and safety to endoscopic stent placement while being associated with fewer symptom recurrence and requirements for re-intervention. [27] Nasoenteric tube feeding is often a useful mode of palliation in patients with malignant GOO with limited life expectancy. Sometimes, percutaneous gastrostomy is required for gastric decompression (venting gastrostomy) in association with nasoenteric tube feeding. If expected survival is more than a month, effort should be made to place antral stent as lack of comfort is the main issue with prolonged nasoenteric tube feeding.
Total parenteral nutrition (TPN) is an alternative option to nasoenteric tube feeding. TPN is also recommended before surgery to improve the nutritional status of patients.
Antroduodenal Stents for Palliation of Malignant Gastric Outlet Obstruction

History
The first antroduodenal stent was placed by Song et al. in 1993 . [28] They placed a Z stent through gastrostomy route. In 1995, the first peroral antroduodenal stent was placed by Strecker et al. [29] Since then, several advancements have been made in the type of stents used and techniques of stent placement.
Indication and contraindication of self-expanding metal stent placement Palliation for malignant GOO is not only limited to improve symptoms but also to improve QoL and allow starting or resuming oral medication. Antroduodenal stents are preferred mode of palliation in groups of patients who have confirmed malignant obstruction with high surgical risk, limited life expectancy, and significant comorbidity.
The contraindications of stent placement are life expectancy <2 weeks, delayed gastric emptying, and concomitant distal gastrointestinal obstruction. [30] 
Technical Aspect
Types of antroduodenal self-expanding metal stents Table 1 shows different types and the characteristics of antroduodenal stents available in market. Antroduodenal stents are made up of different metal alloy, i.e., Elgiloy (stainless steel) and Nitinol (nickel-titanium) alloy and are available in different length, diameter, and expansile forces. In general, antroduodenal stents are either covered or uncovered types. Each type of stents has its own advantages and disadvantages. The main cause of dysfunction of uncovered stent is tumor ingrowth or overgrowth with a frequency of 10%-30%. [31, 32] Although covered stent can overcome the problem of tumor ingrowth or overgrowth, disadvantage includeing stent migration with frequency of 16%-25% is common. [33, 34] A few randomized trials have shown comparable stent patency while using covered or uncovered self-expanding metal stent (SEMS) for palliation of malignant GOO. [33, 35, 36] Various modifications have been made to reduce the frequency of stent migration. Example of such type stent is WAVE stent. WAVE stent has been designed to reduce radial force and indentation in the central part of the uncovered flared portions of SEMS at both ends and a lasso at the proximal end that helps in adjustment of the stent position after deployment. A multicenter randomized study compared the safety and efficacy of newly developed WAVE-covered stent (with antimigration properties) with uncovered antroduodenal stent in malignant GOO due to gastric cancer. Results of this study showed comparable migration rate (9.5% vs. 5.4%) and significantly higher long-term stent patency rate (68.6% vs. 41.2%) in WAVE-covered stent group compared with uncovered stent. [37] Technique of stent placement Before undertaking the procedure, gastric lavage is required through nasogastric tube for proper visualization and to prevent aspiration. Stent placement is performed by standard technique (www.spreadhealth. in, video; https://youtu.be/ZkI0wn7ZxQ8) using either a forward-viewing therapeutic scope or a side-viewing duodenoscope with a working channel diameter of ≥3.7 mm [ Figure 1 ]. One study showed a comparable technical and clinical success rate when SEMS was placed through forward-viewing therapeutic endoscope or side-viewing duodenoscope for palliation of malignant distal duodenal obstruction. [11] Patients are sedated with midazolam (5-10 mg) and/or propofol during SEMS placement. The endoscope is inserted carefully and the GOO is evaluated endoscopically. Water-soluble contrast medium is injected under fluoroscopic guidance to assess the site and length of the obstruction. The obstruction should be negotiated using a standard biliary guidewire and an endoscopic retrograde cholangiopancreatography catheter. The stent delivery system should be inserted over the guidewire through the working channel of endoscope and deployed across the stricture with endoscopic as well as fluoroscopic guidance.
Technical success
In various studies, technical success is defined as adequate positioning and deployment of stent across the stricture with relief of obstruction, usually confirmed by performing water-soluble contrast study. Technical success rate in various studies is 92%-100%. [38] [39] [40] [41] [42] Jung et al. [38] evaluated outcomes of endoscopically placed SEMS in 220 patients with malignant GOO, and technical success was achieved in 96.8% (213/220). Causes of technical failure were inability to pass guidewire, acute angulation, and far distal obstruction site. Results of the other studies also showed that common reasons for technical failure include the inability to pass a guidewire across the stricture, failure of the delivery system to release the stent, failure of stent deployment, and stent migration during procedure. [25, 40] Older studies [43] had a comparatively less technical success rate, probably because of SEMS used in earlier years were not specifically designed for antral use. A few studies reported balloon dilatation of stent because of inadequate SEMS expansion. [4] Overall, complete obstruction and inability to pass guidewire across the obstruction remains the major factors behind technical failure.
Clinical Aspect
Clinical success
For objective assessment of level of GOO, a scoring system was created by Adler and Baron. [13] This GOO scoring system (GOOSS) is considered as a standard scoring system for assessing treatment response in patients with GOO. According to this scoring system, a score of 0 stands for no oral intake, a score of 1 for ability to consume liquids only, a score of 2 for soft solids, and a score of 3 for a low residue or full diet. [13] In different studies, clinical success is defined as GOOSS >2 or improvement in GOOSS ≥1 point within a week after procedure.
Clinical success rates in various studies range from 67% to 97%. Shin et al. [44] [45] included 32 studies and 606 patients with malignant GOO in whom stent placement was attempted. Clinical success was achieved in 89% of 589 patients. Mean time for symptom resolution after stent placement was 4 days. Majority of clinical failures were due to disease-related factors. However, different types of stents were used in different studies cited in this systemic review, and no subgroup analysis was done between the different types of stents to compare clinical outcomes.
Jung et al. [38] assessed outcomes of endoscopic SEMS placement (fully covered, partially covered, and uncovered) in 220 patients with malignant GOO. Clinical success rates were similar following the placement of fully covered, partially covered, and uncovered SEMSs (93.8% vs. 88.3% vs. 84.2%, respectively, P = 0.476). Rademacher et al. [46] found that the presence of carcinomatosis was associated with a significantly lower clinical success rate compared to patients with no evidence of peritoneal disease (66.7% vs. 88.6%, P = 0.036).
Yamao et al. [47] conducted a multicenter retrospective study in Japan; the rate of clinical failure after stent placement was 11.7% (32/274), and the identified predictive factors for clinical failure were Karnofsky Performance Score (KPS) ≤50 (OR, 6.63; 95% CI, 2.89-15.20; P < 0.01) and stenosis sites ≥3 in numbers (OR, 6.11; 95% CI, 2.16-17.30; P < 0.01).
Survival after stent placement
Results of multiple studies showed that median survival ranges from 49 to 195 days. [1] [2] [3] [4] Oh et al. [39] placed partially covered SEMS in 20 patients to palliate GOO. Five patients died without stent occlusion within 8 weeks. Overall median survival after stent placement was 81 days (IQR: 42.25-153.25)
Rademacher et al. [46] included a larger number of patients (62) with and without evidence of peritoneal carcinomatosis. There was no significant difference in overall survival between patients with or without peritoneal carcinomatosis (median: 48 vs. 70 days, P = 0.21), but patients showed significantly longer survival after clinical success of SEMS placement compared to those experiencing clinical failure (median: 14.5 vs. 75 days, P = 0.0003). Another study showed a median patient survival of 124 days (IQR: 55.5-224.0 days), being significantly longer in patients with clinical success than in those with failure after stent insertion (188.35 ± 12.93 vs. 80.89 ± 20.19 days, P = 0.002). [38] Oh et al. [48] studied survival and clinical outcome after stent placement for GOO due to pancreatic cancer compared with nonpancreatic cancer. Overall survival was shorter in patients with pancreatic cancer (13.7 vs. 17.1 months; P = 0.004). Chemotherapy after sent placement and the absence of distant metastasis were associated with better survival in both the groups (pancreatic cancer: chemotherapy vs. no chemotherapy, 5.4 vs. 1.5 months, P = 0.0001; metastasis vs. no metastasis, 1.8 vs. 4.6, P = 0.005; nonpancreatic cancer: chemotherapy vs. no chemotherapy, 9.2 vs. 1.8, P = 0.001; metastasis vs. no metastasis, 2.1 vs. 6.1, P = 0.009).
Overall median survival after stent placement for GOO is influenced by underlying comorbidities, patient performance status and clinical success.
Quality of life
There are limited data regarding any improvement in QoL after SEMS placement. In a review of published literature from 2000 to 2007, none of the studies had used standardized questionnaire for objective assessment of QoL before and after SEMS placement. In a review article, 7 out of 41 studies used the Karnofsky Performance Scale before and after stent treatment. [49] In 2009, Van Hooft et al. [32] studied (DUOFLEX study) the effect in QoL after placement of Wallflex enteral stents in 51 patients with malignant GOO. They found no improvement in global QoL assessed by quality of life questionnaires (European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 instrument, EQ-5D including the EuroQol Visual Analog Scale). Schmidt et al. [50] did a prospective observational study to assess QoL in patients with malignant GOO after palliation (both surgical and endoscopic). Endoscopic palliation was done in 24 out of 50 enrolled patients. Overall survival was 94 days (median) in endoscopic stent placement group. EORTC QLQ-C30 instrument was used to assess functional status and cancer-related symptoms. After 3 months of palliation, role functioning, physical functioning, global health status (QOL), and nausea/vomiting improved compared to baseline, but statistically significant difference was seen only in QOL and nausea/vomiting. Cognitive and social functions and other judged parameters assessed by the same instrument such as pain and appetite were not changed after intervention. In the same study, gastric-specific symptoms (assessed using EORTC QOL-STO22 instrument) such as dysphagia, eating restriction, dry mouth, and reflux were significantly improved after stent placement.
Adverse events
Complications of endoscopic SEMS placement can be classified as immediate (within 24 h of procedure), early (from 96 h to 2 weeks of procedure), and late complications, which occur more than 2 weeks after stent placement. [40, 51, 52] Immediate and early complications include problems related to sedation, aspiration, bleeding, perforation, stent malposition, and stent migration. Commonly occurring late complications are stent migration, stent occlusion (food impaction and tumor ingrowth and overgrowth), bleeding, perforation, and fistula formation. Complication rate in various studies ranges 0%-30%. [6, 13, 53] In a study by Kim et al. , [54] restenosis occurred in 5/43 (11.6%) patients, mainly within 4 weeks of stent placement, which could be managed successfully by another stent placement. Two patients (3.8%) had distal stent migration, which required another overlapping stent placement. Stent occlusion due to tumor overgrowth occurred in one patient (1.9%) at 331 day and tumor ingrowth in 14 patients (26.4%) at a mean of 78.4 day after stent placement. Median stent patency period was 187 days.
In a systemic review by Dormann et al., [45] overall complication rate was 28%. Perforation (1.2%), bleeding (0.5%), stent obstruction (17.2%), and stent migration (5.1%) were most commonly occurring major complications. Procedure-related pain occurred in 2.5%.
In a prospective study by Havemann et al., [55] duodenal perforation occurred in 2 out of 45 patients during guidewire negotiation or biliary stent placement, and both complications were managed surgically.
A systematic review and meta-analysis compared the outcomes after covered and uncovered SEMS placement. [34] Yamao et al. [47] conducted a multicenter retrospective study in Japan and assessed the predictors of outcome of SEMS placement in malignant GOO. The early adverse events consisted largely of jaundice (n = 17, 6.1%). The early adverse events occurred in 28/277 patients, including hyperamylasemia (1.1%), aspiration pneumonia (1.1%), pancreatitis (0.7%), bleeding (0.7%), and perforation (0.4%). The late adverse events (21/277) included bleeding (3.2%), jaundice (2.5%), and perforation (1.8%). The predictors of adverse events were use of uncovered stents (hazard ratio [HR] for covered stents = 0.27; 95% CI, 0.10-0.69; P < 0.01) and lack of chemotherapy after stent placement (HR for chemotherapy after stenting = 0.42; 95% CI, 0.19-0.95; P = 0.04). Deployment of two stents in the same session (HR, 854.88; 95% CI, 11.36-64356.6; P < 0.01) was associated with perforation. The rate of overall stent dysfunction during follow-up was 16.6% (46/277), which included tumor ingrowth in 5.8% (16/277), overgrowth in 4.0% (11/277), and stent migration in 4.0% (11/277) . The use of covered stent was a predictor of stent migration (P < 0.01), while uncovered stent did not predict tumor in-growth. In a recent study from our centre on 114 patients, antral stent could be placed in a shorter time using forward-viewing therapeutic endoscope than a side-viewing endoscope. [56] 
Conclusion
Diagnosis of malignant GOO is based on clinical history, examination, imaging, and endoscopy. Endoscopic enteral stent placement is a safe and effective mode of palliation for malignant GOO. Technical success rates of enteral stent placement are very high, and clinical success rates were lower than technical success rates. This discrepancy between technical success and clinical success might be partially explained by underlying GI dysmotility, [57] distal obstruction secondary to peritoneal carcinomatosis, and anorexia associated with advanced malignancy. Recurrent obstructive symptoms may arise due to tumor ingrowth or overgrowth in a subset of patients, which can be successfully managed with repeat endoscopic stent placement. Finally, enteral stent placement is also associated with improvement in QoL.
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